Item 7.01. Regulation FD Disclosure
On
The information furnished pursuant to Items 7.01 and 9.01, including the information set forth in Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Forward-Looking Statements
This Current Report on Form 8-K may contain "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995. Statements
that are not historical in nature, and which may be identified by the use of
words such as "expects," "assumes," "projects," "anticipates," "estimates," "we
believe," "could be" and other words of similar meaning, are forward-looking
statements. These risks and uncertainties include those risk factors discussed
in Part I, "Item 1A. Risk Factors" of our Annual Report on Form 10-K for the
year ended
Factors that could cause actual results to differ materially from those contemplated by the forward-looking statements include:
? general economic, political and market conditions; ? our ability to generate the required productivity, stability, purity, performance, cost, safety and other data necessary to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; ? our ability to retain and attract employees, consultants, directors and advisors; ? our ability to implement and successfully carry out Dyadic's and third parties' research and development efforts; ? our ability to obtain new license and research agreements; ? our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties; ? competitive pressures and reliance on our key customers and collaborators; ? the pharmaceutical and biotech industry, governmental regulatory and other agencies' willingness to adopt, utilize and approve the use of the C1 gene expression platform; ? the risk of theft, misappropriation or expiration of owned or licensed proprietary and intellectual property, genetic and biological materials owned by us and/orDanisco US, Inc. andVTT Technical Research Centre of Finland Ltd ; ? speculative nature and illiquidity of equity securities received as consideration from sub-licenses; and ? the impact of the novel coronavirus identified as "COVID-19" on our business and operating results.
There may be other factors that may cause our actual results to differ materially from the forward-looking statements. Our actual results, performance or achievements could differ materially from those expressed in, or implied by, the forward-looking statements. We can give no assurances that any of the events anticipated by the forward-looking statements will occur or, if any of them do, what impact they will have on our results of operations and financial condition. You should carefully read the factors described in the "Risk Factors" section of the 2020 Annual Report for a description of certain risks that could, among other things, cause our actual results to differ from these forward-looking statements.
Item 9.01 Financial Statements and Exhibits (d) Exhibits The following exhibit is being furnished herein: Exhibit Number Description 99.1 Dyadic International Presentation 104 Cover page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source